Insmed Incorporated (NASDAQ:INSM) Given Consensus Rating of "Buy" by Brokerages

Shares of Insmed Incorporated (NASDAQ:INSM - Get Free Report) have received a consensus rating of "Buy" from the sixteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Sixteen investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $96.73.

Several equities research analysts have recently issued reports on the company. Royal Bank of Canada reissued an "outperform" rating and issued a $100.00 target price on shares of Insmed in a research note on Wednesday, March 19th. Jefferies Financial Group began coverage on shares of Insmed in a research note on Tuesday, May 13th. They issued a "buy" rating and a $105.00 price objective for the company. UBS Group dropped their target price on Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Stifel Nicolaus reduced their price target on Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a report on Friday, February 21st. Finally, Guggenheim reaffirmed a "buy" rating and issued a $101.00 price objective on shares of Insmed in a research report on Tuesday, February 25th.

Insider Buying and Selling at Insmed

In related news, insider Michael Alexander Smith sold 4,407 shares of Insmed stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $67.81, for a total value of $298,838.67. Following the completion of the sale, the insider now directly owns 92,203 shares in the company, valued at $6,252,285.43. This trade represents a 4.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO William Lewis sold 18,750 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $77.03, for a total transaction of $1,444,312.50. Following the sale, the chief executive officer now directly owns 334,186 shares in the company, valued at approximately $25,742,347.58. This represents a 5.31% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 161,115 shares of company stock worth $11,182,832 over the last quarter. Insiders own 3.00% of the company's stock.

Hedge Funds Weigh In On Insmed

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INSM. Cullen Frost Bankers Inc. raised its position in Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 221 shares during the last quarter. Elequin Capital LP acquired a new stake in shares of Insmed during the 4th quarter worth approximately $28,000. Steward Partners Investment Advisory LLC grew its stake in shares of Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 163 shares during the period. NBC Securities Inc. purchased a new position in shares of Insmed during the 1st quarter valued at approximately $49,000. Finally, V Square Quantitative Management LLC lifted its stake in shares of Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 248 shares during the period.

Insmed Stock Down 1.3%

Shares of INSM opened at $72.74 on Friday. The company has a market capitalization of $13.25 billion, a PE ratio of -13.01 and a beta of 0.84. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed has a 12-month low of $55.74 and a 12-month high of $84.91. The business's 50 day moving average is $69.25 and its 200 day moving average is $73.03.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The firm had revenue of $92.82 million for the quarter, compared to analysts' expectations of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business's quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.06) EPS. Research analysts expect that Insmed will post -4.56 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.